ADMA Biologics Inc (ADMA)

Comprehensive analysis of ADMA Biologics Inc. (NASDAQ: ADMA) as of October 26, 2023:

Company Profile:

ADMA Biologics Inc., based in Ramsey, New Jersey, was founded in 2020. Their stock began trading under the stock symbol ADMA on October 8, 2021 (Nasdaq). They offer a comprehensive discovery service for therapeutic antibody discovery with a particular focus on the discovery of nanomolar, high specificity monoclonal antibodies and related biologics for infectious diseases, autoimmune disorders, and cancer. They accomplish their research and discovery by utilizing its unique technology, the RiboMab Platform, and expertise. This innovative platform rapidly generates novel and proprietary, fully human monoclonal antibodies. The CEO & President, Adam M. Grossman and the Chief Business Officer, Steven D. Shall, head this organization. They have an experienced executive and scientific advisory board, including experts in drug discovery.

Top Products and Market Share:

• ADMA's discovery services are used by several pharmaceutical, biotechnology companies, academic and research organizations. Their client-driven research and expertise have allowed for significant discoveries of novel antibodies for several diseases and disorders. They currently have 21 ongoing and 31 completed programs for various autoimmune, oncology, viral, bacterial & infectious, and neurological applications.

• Determining their market exact share of the antibody discovery services market is difficult because of its relatively recent nature and diverse nature. However, the global antibody research and drug development service market reached a total market revenue of 6.7 billion US dollars in 2024.

• They face strong market competition in this sector, including:

  • WuXi Antibody Discovery Services: A leader with over 34% market share, focusing on end-to-end antibody drug discovery.
  • Apta BioPharma Discovery and Development Services (APBI-D&D): Offering similar antibody discovery, development services, as well, with strong market presence.
    • Cell and Gene Discovery and Development (CELG-D&D): This competitor also offers similar services and boasts over 348 ongoing antibody discovery and development preclinical programs.

Total Addressable Market:

The global Antibody Discovery and Development Services industry is valued at $6.7B in 2023 and has witnessed an over a 50.55% compound annual growth rate between 2017 - 2023 and projected an estimated market size value of over $51,028.3 million USD by the time we get to 2035. This growth aligns closely with the rapid rise of the biotechnology and biopharmaceutical sectors, particularly in biologics & therapeutic antibodies and increased R&D spending by drug developers.

Financial Highlights:

The company is still in early development without having generated revenue.

• Their cash- and cash equivalents balance was $384.4M, $5.1M more than June 30.
• Net loss reduced 11.1% YoY to 1 $5.41 Million.

Shareholder Returns and Growth Potential:

Their stock price has risen 383.82% since IPO on October 28, 2022. This is an indication their stock price has a high degree of volatility. The company's lack of revenue and profitability makes traditional valuation measures like P/E useless in determining its estimated market value. However, they continue developing innovative technologies, such as RiboMab, with the possibility of lucrative returns in their later growth stages and beyond with successful clinical trials, drug discovery success, potential acquisitions or future product launches and strategic initiatives.

Market Dynamics & Competitors:**

This sector is undergoing rapid innovation and expansion, fueled largely by growth within biopharmaceutical research and growing adoption and demand in therapeutic monoclonal antibodies, with increasing applications.

**Key Competitors in the antibody discovery services segment include:

• Abzena Group Plc ( ABZN ): Market Share -2.112%. -Catalent (CTLT - 3.02% Market Share ) -Evotec SE(EVTC -2.42 % Market Share )

Challenges and future opportunities:

• They face the challenge and opportunity that come hand in hand with rapid technological change and innovation. They must remain adaptable in the research environment and successfully integrate new discoveries into its offerings.
  • Another significant concern is their reliance and dependence of research partnerships and contractual research engagements for most research funding. These contracts may contain restrictions on future development.
  • Lastly their intellectual proprietary protections may not provide complete and comprehensive protection.

Recent acquisitions (past year):

AI - Based Fundamentals Rating

Based on our AI model, we rate **ADMA a B with potential upside potential for long-term investment. **This score is derived from analyzing the factors described previously, and it shows potential for profitability with successful research and potential market penetration success in a rapidly expanding market segment. However, we must emphasize this assessment is not financial advice.

Disclaimer: Please consult a certified financial expert or planner with any questions regarding making any investment or purchasing stock in this or related companies.

Sources Used:

• ADMA Biologics' website: https://www.admabio.com/ and other publicly disclosed information on the United States Securities and Exchange Commission (SEC) website :
• Financial information and data were retrieved from Yahoo! Finanace
• Market share statistics and competitive landscape insights: Statista
• Industry analysis and size projections sourced from Grand View Research

Conclusion :

ADMA Biologics' presence within the growing Antibody Discovery & Development service market presents significant opportunity for future revenue generation, profitability potential, as well as continued development of their unique technology, RiboMab and future therapeutic discoveries. However it is essential to remember their current developmental state and potential risks before making an investment, and it is highly recommended investors research the market in depth.

I trust this overview assists your research inquiries, and please remember this should *in no way, shape, or manner serve as financial advice and should not supersede the expertise required by an experienced, licensed, and recognized individual such as a Certified Financial Planner (CFP).